Posted by Shawn. T. on November 5, 2002, at 0:51:30
In reply to Abilify..anyone know the date for arrival?, posted by ross c on November 4, 2002, at 10:06:13
Bristol-Myers Squibb's web site states that they anticipate its launch date to be fourth quarter 2002. I would expect it to be released sometime in the next three months. I'll give you a quick overview of the drug. Abilify, also known as aripiprazole, is an agonist at presynaptic dopamine D2 receptors and an antagonist at postsynaptic D2 receptors (in other words, it is a D2 partial agonist). It also antagonizes serotonin 5-HT2A receptors and is a partial agonist at 5-HT1A receptors. The appeal of the drug over other atypical antipsychotics is that it is likely to reduce negative and depressive symptoms to a greater degree. It also lacks risperidone's effects on prolactin levels. Abilify is unlikely to cause extrapyrimidal side effects. Perhaps the biggest appeal for some people will be the decreased risk of weight gain associated with the drug (possibly due to a lack of action at 5-HT2C receptors). Abilify seems to be the immediate successor to the atypical antipsychotics.
Shawn
poster:Shawn. T.
thread:126402
URL: http://www.dr-bob.org/babble/20021101/msgs/126472.html